Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

110
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
110
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

639
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
639
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

115
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
115
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

468
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
468
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

417
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
417
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 心血管医学と血液学
  9. 心臓病 (心血管疾患を含む)
  11. 異なる治療介入におけるldl-cの低下と心血管リスクの減少との関連:体系的レビューとメタ解析

異なる治療介入におけるLDL-Cの低下と心血管リスクの減少との関連:体系的レビューとメタ解析

Michael G Silverman1, Brian A Ference2, Kyungah Im1

  • 1TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

JAMA
|September 28, 2016

関連する実験動画

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K

PubMed で要約を見る

まとめ
この要約は機械生成です。

スタチンはLDL受容体の発現を増加させる治療法であり,LDL-Cを低下させるごとに,同様の心血管リスクの減少を示している. LDL- Cのレベルを下げることは,主予防と二次予防の両方で主要な冠動脈イベントの減少と関連しています.

科学分野:

  • 心血管医学
  • 薬理学について
  • 臨床試験

背景:

  • 低密度脂質タンパク質コレステロール (LDL- C) を低下させるためのスタチン以外の治療法の臨床的効果は完全に理解されていません.
  • 様々なLDL-Cを下げる戦略の比較的効果を評価することは,心血管リスク管理において極めて重要です.

研究 の 目的:

  • 異なるスタチンおよび非スタチン療法におけるLDL-C減少と心血管リスクの関連性を評価する.
  • ランダム化臨床試験における様々なLDL-C低下介入の有効性を比較する.

主な方法:

  • ランダム化臨床試験のデータを元にメタ回帰分析が行われました.
  • 対象となった研究は1966年から2016年7月までの間,MEDLINEとEMBASEのデータベースを検索したものです.
  • 49件の試験から312,175人の参加者のデータを分析し,主要血管疾患に焦点を当てた.

主要な成果:

  • スタチンは,LDL受容体の上昇調節によって作用し,LDL- Cの減少による主要な血管疾患の相対リスク (RR) が類似していることが示された.
  • 1 mmol/ LのLDL- C減少ごとに,主要血管疾患のRRは,スタチンの場合0. 77,非スタチンの場合0. 75でした.
  • LDL- C値の低下は,一次予防と二次予防の両方で,主要な冠動脈イベントの減少率と有意に関連していました.

関連する実験動画

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K

結論:

  • スタチンは,特定の非スタチンの治療法 (例えば,エゼチミブ) により,LDL-Cを低下させることで,比較可能な心血管リスクの減少をもたらします.
  • LDL-C値の低下は,大動脈事件の発生率の減少と一貫して関連しています.
  • これらの発見は,心臓血管疾患の予防における包括的なLDL-C低下戦略の役割を支持しています.